A multicenter, open-label phase II clinical trial of combined MEK plus EGFR inhibition for chemotherapy-refractory advanced pancreatic adenocarcinoma

Andrew H. Ko, Tanios Bekaii-Saab, Jessica Van Ziffle, Olga M. Mirzoeva, Nancy M. Joseph, Amir Ali Talasaz, Peter Kuhn, Margaret A. Tempero, Eric A. Collisson, R. Kate Kelley, Alan P. Venook, Elizabeth Dito, Anna Ong, Sharvina Ziyeh, Ryan Courtin, Regina Linetskaya, Sanaa Tahiri, W. Michael Korn

Research output: Contribution to journalArticlepeer-review

63 Scopus citations

Fingerprint Dive into the research topics of 'A multicenter, open-label phase II clinical trial of combined MEK plus EGFR inhibition for chemotherapy-refractory advanced pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences